Browse Category

NASDAQ:LAKE News 11 December 2025

Biggest Stock Losers Today: Oracle’s AI Shock and Micro‑Cap Meltdowns Rock the U.S. Market (Dec. 11, 2025)

Biggest Stock Losers Today: Oracle’s AI Shock and Micro‑Cap Meltdowns Rock the U.S. Market (Dec. 11, 2025)

As Wall Street moves past the Federal Reserve’s latest interest‑rate cut, traders are staring at a very different story on their screens today: a cluster of heavy losers across U.S. stocks, led by a double‑digit plunge in Oracle and spectacular collapses in a handful of thinly traded micro‑caps. On Thursday, December 11, 2025, U.S. index futures are in the red despite the Fed’s 25‑basis‑point rate cut to a 3.5%–3.75% target range. The trigger: Oracle’s earnings and spending plans, which have revived worries that AI capital expenditure is outrunning returns and stoked talk of an “AI bubble.” Reuters+2Reuters+2 Below is a

Stock Market Today

MARA stock jumps 22% into weekend as bitcoin whipsaws; Monday risk test looms

MARA stock jumps 22% into weekend as bitcoin whipsaws; Monday risk test looms

7 February 2026
MARA shares jumped 22.4% to $8.24 Friday, trading higher after hours, as the company moved $87 million in bitcoin to major custodians. About 82.4 million MARA shares changed hands. Bitcoin hovered near $68,928 Saturday. A MARA filing showed its general counsel had shares withheld for taxes on vested stock units, not an open market sale.
Apple stock (AAPL) set for Monday test as memory-chip crunch revives iPhone price question

Apple stock (AAPL) set for Monday test as memory-chip crunch revives iPhone price question

7 February 2026
Apple shares closed up 0.8% at $278.12 Friday, then slipped 0.3% after hours. A global DRAM shortage is raising component costs, putting pressure on Apple’s pricing ahead of its Feb. 24 shareholder meeting. CEO Tim Cook said memory prices will rise “sharply” but gave no details on possible iPhone price hikes. Investors await signals before next week’s U.S. inflation data.
Roivant stock surges on brepocitinib skin-disease data; what to watch into Monday

Roivant stock surges on brepocitinib skin-disease data; what to watch into Monday

7 February 2026
Roivant shares surged 22.4% to $25.82 after Phase 2 data showed its drug brepocitinib outperformed placebo in cutaneous sarcoidosis, with no serious adverse events. The company plans a Phase 3 trial in 2026 and has filed for FDA approval in dermatomyositis. Quarterly revenue reached $2 million, with a $313.7 million loss. Cash holdings stood at $4.5 billion.
Go toTop